Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.48)
# 928
Out of 5,090 analysts
226
Total ratings
46.48%
Success rate
20.96%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $5.63 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $26.59 | +5.32% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $166.39 | -9.85% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $148.41 | +3.09% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $15.16 | -7.65% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $72.73 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $9.61 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $30.96 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $38.25 | +51.63% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $29.30 | +46.78% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $66.71 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.30 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $153.75 | +0.81% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.39 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $20.30 | +72.41% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.23 | +148.80% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.95 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.75 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.48 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.39 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $23.14 | +46.96% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $47.47 | +5.33% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.93 | -15.61% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.36 | +1,001.93% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.07 | +275.59% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $44.69 | +29.78% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.61 | +68,222.98% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $6.32 | +1,165.82% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $0.96 | +213.41% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $4.42 | +149.15% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.69 | +56.05% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.84 | +2,357.94% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.74 | +629.93% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $27.18 | +635.84% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.64 | +144.65% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $3.32 | +622.89% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $2.04 | +6,976.17% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.26 | +216.61% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $63.10 | -38.19% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $85.15 | -82.38% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.54 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $5.31 | +3,289.83% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.63
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $26.59
Upside: +5.32%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $166.39
Upside: -9.85%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $148.41
Upside: +3.09%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $15.16
Upside: -7.65%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $72.73
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.61
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.96
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $38.25
Upside: +51.63%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $29.30
Upside: +46.78%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $66.71
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.30
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $153.75
Upside: +0.81%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.39
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $20.30
Upside: +72.41%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.23
Upside: +148.80%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.95
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.75
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.48
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.39
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $23.14
Upside: +46.96%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $47.47
Upside: +5.33%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.93
Upside: -15.61%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.36
Upside: +1,001.93%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.07
Upside: +275.59%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $44.69
Upside: +29.78%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.61
Upside: +68,222.98%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $6.32
Upside: +1,165.82%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $0.96
Upside: +213.41%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $4.42
Upside: +149.15%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.69
Upside: +56.05%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.84
Upside: +2,357.94%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.74
Upside: +629.93%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $27.18
Upside: +635.84%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.64
Upside: +144.65%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $3.32
Upside: +622.89%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $2.04
Upside: +6,976.17%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.26
Upside: +216.61%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $63.10
Upside: -38.19%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $85.15
Upside: -82.38%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.54
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $5.31
Upside: +3,289.83%